Mouse models of human non-small-cell lung cancer: raising the bar.

Lung cancer is a devastating disease that presents a challenge to basic research to provide new steps toward therapeutic advances. The cell-type-specific responses to oncogenic mutations that initiate and regulate lung cancer remain poorly defined. A better understanding of the relevant signaling pathways and mechanisms that control therapeutic outcome could also provide new insight. Improved conditional mouse models are now available as tools to improve the understanding of the cellular and molecular origins of adenocarcinoma. These models have already proven their utility in proof-of-principle experiments with new technologies including genomics and imaging. Integrated thinking to apply technological advances while using the appropriate mouse model is likely to facilitate discoveries that will significantly improve lung cancer detection and intervention.

[1]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2]  H. Popper,et al.  Atypical Adenomatous Hyperplasia of the Lung: A Probable Forerunner in the Development of Adenocarcinoma of the Lung , 2001, Modern Pathology.

[3]  Anton Berns,et al.  The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. , 2003, Cancer research.

[4]  J. Ritter Tumors of the Lower Respiratory Tract: Atlas of Tumor Pathology , 1996 .

[5]  L. D. Nielsen,et al.  Surfactant protein C expression in urethane-induced murine pulmonary tumors. , 2000, The American journal of pathology.

[6]  J. Minna,et al.  Focus on lung cancer. , 2002, Cancer cell.

[7]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[8]  C. Der,et al.  Increasing Complexity of the Ras Signaling Pathway* , 1998, The Journal of Biological Chemistry.

[9]  David A. Williams,et al.  Critical Roles for Rac1 and Rac2 GTPases in B Cell Development and Signaling , 2003, Science.

[10]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[11]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[13]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[14]  D. Bar-Sagi,et al.  Differential Activation of the Rac Pathway by Ha-Ras and K-Ras* , 2001, The Journal of Biological Chemistry.

[15]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[16]  David G Kirsch,et al.  Future of Early Detection of Lung Cancer: The Role of Mouse Models , 2005, Clinical Cancer Research.

[17]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[18]  S. Linn,et al.  Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene , 2001, Oncogene.

[19]  F. Shepherd,et al.  Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. , 2003, Lung cancer.

[20]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[21]  D. Warburton,et al.  Embryonic mouse lung epithelial progenitor cells co-express immunohistochemical markers of diverse mature cell lineages. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[22]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[23]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Nettesheim Cells of origin of primary pulmonary neoplasms in mice. , 1991, Experimental lung research.

[25]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[26]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[27]  T. Jacks,et al.  Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer , 2005, Nature Medicine.

[28]  J. Mesirov,et al.  An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis , 2005, Nature Genetics.

[29]  John G. Collard,et al.  Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours , 2002, Nature.

[30]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[31]  B. Stripp,et al.  Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. , 2002, The American journal of pathology.

[32]  J. Minna,et al.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. , 1990, Oncogene.

[33]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[34]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[35]  Vasilis Ntziachristos,et al.  Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. Rom,et al.  Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. , 1995, Cancer research.

[37]  J. Whitsett,et al.  Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice. , 1992, Cancer research.

[38]  J. Sebat,et al.  Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. , 2003, Genome research.

[39]  T. Jacks,et al.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Kos,et al.  Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking , 2000, British Journal of Cancer.

[41]  L. Chin,et al.  High-resolution genomic profiles of human lung cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Der,et al.  Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation , 1995, Molecular and cellular biology.

[43]  S. Hirohashi,et al.  Association of point mutation in c‐Ki‐ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes , 1990, Cancer.

[44]  Zang Ai-hua,et al.  Stem Cells,Cancer and Cancer Stem Cells , 2005 .

[45]  E. Andrechek,et al.  Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[47]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[48]  R. Chiba,et al.  Atypical adenomatous hyperplasia of the lung and its differentiation from adenocarcinoma. Characterization of atypical cells by morphometry and multivariate cluster analysis , 1993, Cancer.

[49]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[50]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[51]  S. Lowe,et al.  Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. , 1998, Genes & development.

[52]  B Nebiyou Bekele,et al.  Murine Lung Tumor Measurement Using Respiratory-Gated Micro-Computed Tomography , 2005, Investigative radiology.

[53]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[54]  G. Stoner,et al.  Glyceraldehyde-3-phosphate dehydrogenase and other enzymatic activity in normal mouse lung and in lung tumors. , 1991, Experimental lung research.

[55]  C. Halbert,et al.  Sheep retrovirus structural protein induces lung tumours , 2005, Nature.

[56]  K. R. Fitch,et al.  Genetics of dark skin in mice. , 2003, Genes & development.

[57]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[58]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[59]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[60]  Erika Check,et al.  Proteomics and cancer: Running before we can walk? , 2004, Nature.

[61]  I. Weissman,et al.  JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells , 2004, Cell.

[62]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[63]  F. McCormick,et al.  An essential role for Rac in Ras transformation , 1995, Nature.

[64]  G. B. Dermer Origin of bronchioloalveolar carcinoma and peripheral bronchial adenocarcinoma , 1982, Cancer.

[65]  R Weissleder,et al.  In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. , 2000, Cancer research.

[66]  J. Kutok,et al.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. , 2004, The Journal of clinical investigation.

[67]  R. Weissleder Molecular imaging: exploring the next frontier. , 1999, Radiology.

[68]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[69]  D. Woods,et al.  Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.

[70]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.